<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13020">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00434057</url>
  </required_header>
  <id_info>
    <org_study_id>20061</org_study_id>
    <nct_id>NCT00434057</nct_id>
  </id_info>
  <brief_title>Evaluation of Pigmented Skin Lesions With MelaFind(R) System</brief_title>
  <official_title>Evaluation of Pigmented Skin Lesions With MelaFind(R) System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MELA Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MELA Sciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to demonstrate that MelaFind®, a new instrument that
      uses machine vision for non-invasive early detection of cutaneous pigmented malignant
      melanoma, is safe and effective. MelaFind® acquires digital images of the lesion with
      illumination in different spectral bands, from visible to near infrared, and automatically
      analyzes these images. Diagnostic accuracy of MelaFind® and that of study dermatologists
      will be evaluated. The reference standard will be final interpretation of lesions by central
      dermatohistopathology.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Sensitivity and Specificity</measure>
    <time_frame>Within 120 days of Data Lock</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Sensitivity is the fraction of correctly identified cases of melanoma. Specificity is the fraction of correctly identified cases of non-melanoma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biopsy Ratio</measure>
    <time_frame>Within 120 days of Data Lock</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of lesions bioopsied to melanomas detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exploratory Analyses</measure>
    <time_frame>Within 365 days of Data Lock</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1383</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Biopsied Pigmented Skin Lesions</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pigmented skin lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MelaFind(R)</intervention_name>
    <description>Biopsy ratio comparison</description>
    <arm_group_label>Biopsied Pigmented Skin Lesions</arm_group_label>
    <other_name>MF100</other_name>
    <other_name>MelaFind Device System</other_name>
    <other_name>MelaFind Device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The lesion is pigmented (i.e., melanin, keratin, blood)

          -  Clinical management of the lesion by the examining dermatologist is either biopsy of
             the lesion in toto, or 3-month follow-up of the lesion

          -  The diameter of the pigmented area is between 2 and 22 millimeters

          -  The lesion is accessible to the MelaFind hand-held imaging device

          -  The patient, or a legally authorized representative, has consented to participate in
             the study and has signed the Informed Consent Form

        Exclusion Criteria:

          -  The patient has a known allergy to isopropyl alcohol

          -  The lesion has been previously biopsied, excised, or traumatized

          -  The skin is not intact (e.g., open sores, ulcers, bleeding)

          -  The lesion is within 1 cm of the eye

          -  The lesion is on mucosal surfaces (e.g., lips, genitals)

          -  The lesion is on palmar hands

          -  The lesion is on plantar feet

          -  The lesion is on or under nails

          -  The lesion is located on or in an area of visible scarring

          -  The lesion contains foreign matter (e.g., tattoo, splinter, marker)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Gutkowicz-Krusin, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Electro-Optical Sciences, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph V Gulfo, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Electro-Optical Sciences, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harold S Rabinovitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Skin and Cancer Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Armand B Cognetta, Jr, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dermatology Associates of Tallahassee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Skin and Cancer Associates</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Tallahassee</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32317</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <lastchanged_date>February 10, 2012</lastchanged_date>
  <firstreceived_date>February 8, 2007</firstreceived_date>
  <firstreceived_results_date>May 26, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pigmented Skin Lesions</keyword>
  <keyword>Dermatology</keyword>
  <keyword>Skin Cancer</keyword>
  <keyword>Melanoma</keyword>
  <keyword>MelaFind</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pigmentation Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Biopsied Pigmented Skin Lesions</title>
          <description>Lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1383"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1382">One patient withdrew from the study after signing the Informed Consent Form</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Biopsied Pigmented Skin Lesions</title>
          <description>Lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1383"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="56"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1056"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="271"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48" spread="18.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="745"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="638"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1383"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity and Specificity</title>
        <description>Sensitivity is the fraction of correctly identified cases of melanoma. Specificity is the fraction of correctly identified cases of non-melanoma.</description>
        <time_frame>Within 120 days of Data Lock</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>All participants with eligible and evaluable lesions were used in analysis of primary outcome measures</population>
        <group_list>
          <group group_id="O1">
            <title>Biopsied Pigmented Skin Lesions</title>
            <description>Lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1257"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sensitivity and Specificity</title>
            <description>Sensitivity is the fraction of correctly identified cases of melanoma. Specificity is the fraction of correctly identified cases of non-melanoma.</description>
            <units>Ratio * 100</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>MelaFind sensitivity to melanoma</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.2" lower_limit="95.1" upper_limit="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>MelaFind specificity for melanoma</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.5" lower_limit="6.1" upper_limit="12.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>MelaFind's sensitivity to cutaneous melanoma and 95% confidence intervals were determined.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.05</p_value>
            <method>exact mid-P</method>
            <param_type>Sensitivity to melanoma</param_type>
            <param_value>98</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>95.1</ci_lower_limit>
            <ci_upper_limit>100</ci_upper_limit>
            <estimate_desc>Of 127 melanomas, 114 melanomas had a pre-biopsy diagnosis of &quot;Melanoma can not be ruled out&quot; or &quot;Not melanoma,&quot; which qualified them for primary endpoint analysis of sensitivity. MelaFind correctly identified 112/114 melanomas.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Specificty of MelaFind and examining dermatologists on the same set of pigmented skin lesions.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.02</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biopsy Ratio</title>
        <description>Number of lesions bioopsied to melanomas detected</description>
        <time_frame>Within 120 days of Data Lock</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>12/2009</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exploratory Analyses</title>
        <time_frame>Within 365 days of Data Lock</time_frame>
        <safety_issue>No</safety_issue>
        <posting_date>02/2010</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Biopsied Pigmented Skin Lesions</title>
          <description>Lesions for which clinical management was prospectively determined to be biopsy of the lesion in toto</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1383"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1383"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joanna Adrian / Director, Clinical Operations and Medical Affairs</name_or_title>
      <organization>Electro-Optical Sciences, Inc.</organization>
      <phone>(914)591-3783 ext 732</phone>
      <email>adrian@eosciences.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
